Table 1.
Parameters | (n) | (%) |
---|---|---|
Age (median; 67 years, range; 46–87) | ||
Gender | ||
Male | 39 | 90.7 |
Female | 4 | 9.3 |
Performance Status | ||
0 | 22 | 51.16 |
1 | 14 | 32.56 |
2 | 7 | 16.28 |
Stage | ||
IIIb | 8 | 18.6 |
IV | 35 | 81.4 |
Histological subtype | ||
Squamous | 14 | 32.6 |
Non-squamous | 29 | 67.4 |
No of metastatic sites | ||
<2 | 22 | 51.2 |
≥2 | 21 | 48.8 |
Metastatic sites | ||
Lung | 30 | 69.8 |
Bones | 16 | 37.2 |
Liver | 6 | 14 |
CNS | 6 | 14 |
Adrenal gland | 8 | 18.6 |
Lymph nodes | 8 | 18.6 |
Peritoneum | 1 | 2.3 |
Pancreas | 1 | 2.3 |
EGFR status | ||
wt | 41 | 95.3 |
mutant | 2 | 4.7 |
ALK status | ||
wt | 43 | 100 |
re-arranged | 0 | 0 |
Smoking status | ||
Non-smoker | 6 | 14 |
Ex-smoker | 12 | 27.9 |
Current | 25 | 58.1 |
Chemotherapy type | ||
Monotherapy | 5 | 11.6 |
Doublet-chemotherapy | 38 | 88.4 |
Best response to treatment | ||
Partial response | 16 | 37.2 |
Stable disease | 12 | 27.9 |
Progressive disease | 11 | 25.6 |
Non-evaluable | 4 | 9.3 |
CNS: central nervous system; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; wt: wild type.